Everlab is an Australian healthtech startup that plans to expand its preventative healthcare platform aimed at private sector consumers and businesses globally, starting with the UK. It’s now raised AU$65M ($45.5M) in a Series A funding to achieve that.
The round was led by Australia-based Airtree Ventures, with participation from UK-based Plural, Left Lane Capital, B2Venture and angel investors including Australian Test cricket captain Pat Cummins.
The new funding will go into global expansion and technology infrastructure, with the UK as the first market outside Australia and New Zealand.
Founded in 2023, Everlab is trying to turn primary care from a reactive system into a preventative one, not unlike similar startups such as Neko Health, which has expanded in Europe, and US-based Function Health, but with a B2B operation running in parallel to the consumer offering.
Its smartphone app brings diagnostics, doctors, specialists, prescriptions, wearables and AI-supported care into one place, giving patients an overall view of their health rather than a mix of test results and appointments from disparate platforms.
Co-founder and CEO Marc Hermann, who previously launched and exited Foodspring out of Berlin, told Pathfounders most healthtech still stops at the ‘transaction’ in that Telehealth sells doctor time, while blood-testing startups sell a snapshot of your health. He said Everlab plans to sit above all these kinds of offerings.
“In the end, you kind of get a point-in-time measurement and lack the ‘so what’,” Hermann told Pathfounders in an interview. “Often the solution is: ‘tough luck, go find the clinician, deal with it yourself’.”
Everlab’s pitch is that preventative healthcare only works if the system knows enough about the patient to act over time. Hermann says its “lifelong care” embeds into existing healthcare infrastructure rather than running in parallel to it.
“In an AI-first world, we believe the provider that knows you the best, aka has the most data and context on you, is the one that’s going to provide the best level of care,” he said.
The company says it now integrates with more than 1,850 health provider locations, works with 180 active clinicians and supports more than 30 wearable devices. It processes over 200,000 health reports a month.
Everlab says it has completed more than 40,000 consultations for 20,000 patients, including corporate customers such as BCG, BHP and Bain & Company. It claims to have processed over 21 million biomarker test results and says more than 25% of members have had health findings flagged that were missed by the existing healthcare system.
However, Hermann argues Everlab is not simply “Function Health for executives”. Function Health, he said, “basically does a blood test, and that is it.” Everlab, he says, can take a patient from blood tests to MRI scans, colonoscopies and specialists, depending on their risk profile.
The model is also not trying to put every clinician under one roof. Hermann says Everlab’s closest competitor is less a testing startup than “a high-end private clinic,” but this time delivered through an asset-light network of specialist partners rather than an in-house clinic stack.
Everlab will enter the UK market via, firstly, self-paying consumers, and secondly, employers, especially via executive health checks, which are often covered by corporate insurance. Longer term, Hermann says the “holy grail” is working with payers, insurers and public healthcare systems.
The company is already a global-approved vendor for corporate clients, including Bain and BCG, giving it a route into the UK via these existing relationships. Hermann said corporate checks are ‘sticky’ because they often start around key-person insurance risk, then become a broader employee health benefit.
For now, the GTM is private-sector preventative care. Hermann says Everlab sees one to two percent of users in some corporate cohorts receiving potentially life-threatening findings, thus it’s hard to dismiss as just another ‘wellness perk’.
Plural partner Carina Namih said in a statement that the opportunity is in the coordination layer: “Every company that has tried to own the patient journey has ended up either selling doctor time by the minute or reselling lab tests with thin margins,” she said. “Everlab is building the layer above both.”
Hermann says Europe may finally be ready for his company. Two years ago, he said, he would have warned founders to “stay the hell away from Europe” because consumers were not used to paying out of pocket for healthcare. But strained public systems, falling quality of care and rising interest in preventative health have changed the market, he said.
